Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis. by Ponticos, M et al.
ARTHRITIS & RHEUMATOLOGY
Vol. 67, No. 1, January 2015, pp 243–253
DOI 10.1002/art.38897
© 2015 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the
American College of Rheumatology. This is an open access article under the terms of the Creative
Commons Attribution NonCommercial License, which permits use, distribution, and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
Failed Degradation of JunB Contributes to Overproduction of
Type I Collagen and Development of Dermal Fibrosis in
Patients With Systemic Sclerosis
Markella Ponticos,1 Ioannis Papaioannou,1 Shiwen Xu,1 Alan M. Holmes,1 Korsa Khan,1
Christopher P. Denton,1 George Bou-Gharios,2 and David J. Abraham1
Objective. The excessive deposition of extracellu-
lar matrix, including type I collagen, is a key aspect in
the pathogenesis of connective tissue diseases such as
systemic sclerosis (SSc; scleroderma). To further our
understanding of the mechanisms governing the dys-
regulation of type I collagen production in SSc, we
investigated the role of the activator protein 1 (AP-1)
family of transcription factors in regulating COL1A2
transcription.
Methods. The expression and nuclear localization
of AP-1 family members (c-Jun, JunB, JunD, Fra-1,
Fra-2, and c-Fos) were examined by immunohistochem-
istry and Western blotting in dermal biopsy specimens
and explanted skin fibroblasts from patients with dif-
fuse cutaneous SSc and healthy controls. Gene activa-
tion was determined by assessing the interaction of
transcription factors with the COL1A2 enhancer using
transient transfection of reporter gene constructs, elec-
trophoretic mobility shift assays, chromatin immuno-
precipitation analysis, and RNA interference involving
knockdown of individual AP-1 family members. Inhibi-
tion of fibroblast mammalian target of rapamycin
(mTOR), Akt, and glycogen synthase kinase 3 (GSK-
3) signaling pathways was achieved using small-
molecule pharmacologic inhibitors.
Results. Binding of JunB to the COL1A2 enhancer
was observed, with its coalescence directed by activation
of gene transcription through the proximal promoter.
Knockdown of JunB reduced enhancer activation and
COL1A2 expression in response to transforming growth
factor . In SSc dermal fibroblasts, increased mTOR/
Akt signaling was associated with inactivation of GSK-
3, leading to blockade of JunB degradation and, thus,
constitutively high expression of JunB.
Conclusion. In patients with SSc, the accumula-
tion of JunB resulting from altered mTOR/Akt signaling
and a failure of proteolytic degradation underpins the
aberrant overexpression of type I collagen. These find-
ings identify JunB as a potential target for antifibrotic
therapy in SSc.
Systemic sclerosis (SSc; scleroderma) is a com-
plex autoimmune disease with unknown etiology. Patho-
genic processes include vascular damage, autoimmunity,
and widespread fibrosis of the skin and internal organs.
Transforming growth factor  (TGF) has been impli-
cated in the development of many fibrotic diseases,
including SSc. TGF is a pleiotropic mediator with a
critical role in wound healing and tissue remodeling.
Consequently, it is of major importance in pathologic
conditions that are characterized by tissue remodeling,
scarring, and fibrosis. TGF regulates the expression of
genes that are part of, or regulate the formation of, the
extracellular matrix (ECM). Type I collagen is an inte-
gral structural component of the ECM, with a major role
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in wound healing and connective tissue remodeling.
Dysregulated or excessive production and deposition of
type I collagen lead to ECM accumulation and, eventu-
ally, tissue fibrosis.
TGF is a potent inducer of the human procol-
lagen type I 2 chain gene (COL1A2). We have recently
described in detail the in vivo mechanism underlying
the transcriptional control of COL1A2, through a com-
plex interaction between its distal enhancer and proxi-
mal promoter, in response to TGF. This far-upstream
enhancer (FUE) region is highly homologous to the
mouse Col1a2 enhancer region (1–4), which is activated
in adult mice during wound healing and fibrosis (5).
Studies exploring the enhancer function have shown
that TGF can also activate COL1A2 via a noncanonical
(Smad-independent) signaling pathway requiring
enhancer/promoter cooperation. This interaction ap-
pears to involve activator protein 1 (AP-1) family mem-
bers and, in particular, an exchange of c-Jun for JunB in
the critical AP-1 site of the enhancer, resulting in
enhancer/promoter coalescence and transactivation of
the transcriptional machinery bound in the promoter, by
the factors bound to the enhancer. Moreover, using
transgenesis, we have shown that interfering with this
mechanism results in the abolition of COL1A2 expres-
sion by fibroblasts in vivo (6).
The AP-1 family of transcription factors (c-Jun,
JunB, JunD, cFos, FosB, Fra-1, and Fra-2) form homo-
dimers and heterodimers as part of a complex mode of
transcriptional regulation and are induced by a large
variety of cellular signals (7–12). AP-1 transcriptional
regulation is known to be involved in many normal and
pathogenic cellular processes (13–16). Recently, the
important roles of the AP-1 family members c-Jun,
c-Fos, and JunD in dermal fibrosis have been described
in patients with scleroderma (17–20).
In this study, we observed that the novel TGF
response element (TRE) located far upstream in the
enhancer of human COL1A2 was active in fibroblasts
from the fibrotic lesions of patients with SSc. We also
found that JunB was activated by TGF and detected
constitutive expression of JunB in SSc dermal fibro-
blasts. Furthermore, inhibition of JunB resulted in the
down-regulation of type I collagen expression by SSc
dermal fibroblasts and reduced the ability of dermal
fibroblasts to migrate into an in vitro wound. We also
delineated a mechanism of JunB overexpression in SSc
dermal fibroblasts, involving mammalian target of rapa-
mycin (mTOR), Akt, and glycogen synthase kinase 3
(GSK-3) signaling.
PATIENTS AND METHODS
Patients and cell culture. Fibroblasts were explanted
from skin biopsy specimens obtained from patients with diffuse
cutaneous SSc or from normal healthy control subjects, and
cultures were established. The affected skin of SSc patients and
skin from an equivalent location in the controls was sampled.
Each of the fibroblast lines used in this study was derived from
a distinct individual. The patients fulfilled the American
College of Rheumatology preliminary criteria for SSc (21).
The fibroblasts were used between passages 2 and 5. During
TGF treatment, the cells were serum-starved for 8 hours.
TGF was added to a final concentration of 2.5 ng/ml.
DNA constructs. The human collagen FUE region has
been previously described by Antoniv et al (2). Details on the
construction of the plasmid vectors used in this study are
available upon request from the corresponding author. Briefly,
construct 378pLAC in the pbgal-Basic Vector (Clontech)
was derived from the 378 COL1A2/Luc plasmid (17). The
genomic DNA between the enhancer and promoter was ex-
cluded from the DNA constructs.
Transient transfections. Transient transfection assays
were performed using FuGene 6 transfection reagent ac-
cording to the manufacturer’s instructions. Briefly, various cell
lines (2  105 cells per transfection) were cultured in vitro and
transfected with 2 g of total plasmid DNA, with pRSVLuc
(0.2 g) as a normalization control, and 6 l of FuGene 6
reagent. The cells were harvested 72 hours posttransfection
using a Dual-Light Chemiluminescent reporter gene assay
system (Tropix) according to the manufacturer’s instructions.
All transfections were performed in triplicate within each
experiment, and each experiment was repeated on more than
3 separate occasions.
Electrophoretic mobility shift assay (EMSA). The
nuclear extracts were prepared and used in EMSA analyses
according to the protocol described in a Promega Gel Shift
Assay Systems kit. Supershift assays were carried out using
specific antibodies raised against c-Jun (sc-45x), JunB (sc-46x),
and JunD (sc-74x) (all from Santa Cruz Biotechnology).
Briefly, double-stranded oligonucleotides were synthesized
and end-labeled using T4 kinase and 32P–-ATP. Labeled
probes were used in binding reactions with nuclear extracts
from cells that had been left untreated or treated with TGF.
Competition was carried out with unlabeled oligonucleotides
(1.75 pmoles/l) of specific transcription factor consensus-
binding sites.
Sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) and Western blot analysis. Fibroblasts
were seeded (2.5  105 cells per well) for 48 hours. The cells
were serum-starved for 12 hours and treated with or without
TGF (R&D Systems) at 4 ng/ml for a further 24 hours. The
cells were analyzed by SDS-PAGE, followed by Western
blotting. The antibodies against c-Jun, JunB, and JunD (all
from Santa Cruz Biotechnology) and an anti–procollagen 1
antibody (Southern Biotechnology) were used.
RNA inhibition using small interfering RNA (siRNA).
Human JunB siRNA target sequences were obtained from
Dharmacon (JunB siGenome SMARTpool reagent) and used
according to the manufacturer’s instructions. Transfection into
explanted human dermal fibroblasts was achieved using Oligo-
fectamine transfection reagent (Invitrogen) according to the
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manufacturer’s instructions. The siRNA were transfected at
concentrations of 10 nM and 25 nM. Scrambled control siRNA
(K-002800; Dharmacon) were also used and transfected at a
concentration of 25 nM.
Chromatin immunoprecipitation (ChIP) assay. ChIP
assay was performed using a commercially available kit (Up-
state Biotechnology), according to the manufacturer’s in-
structions, on primary human dermal fibroblasts that were left
untreated or treated with TGF. Briefly, DNA–protein com-
plexes were immunoprecipitated with antibodies to RNA
polymerase II, c-Jun, JunB, or JunD (Santa Cruz Biotechnol-
ogy). Polymerase chain reaction amplifications were carried
out with the appropriate primers spanning the human COL1A2
promoter and enhancer. These primers are specific to human
DNA, as previously reported (6).
Immunohistochemistry. Dermal biopsy specimens ob-
tained from patients with diffuse cutaneous SSc or healthy
controls were postfixed in neutral buffered formalin and
paraffin embedded. Sections (3 m) were cut, dewaxed, and
incubated with H2O2 (3%) at room temperature for 10 minutes
in the dark. When required, antigen retrieval was performed
using hot citrate buffer (0.01M, pH 6.0) for 10 minutes. The
sections were incubated in blocking serum (20%) for 10
minutes and washed with phosphate buffered saline. Sections
were incubated with primary antibodies for procollagen
(Abcam) or for c-Jun, JunB, or JunD (all from Santa Cruz
Biotechnology). Specificity of staining was confirmed by as-
sessing control dermal biopsy sections incubated with isotype-
matched irrelevant control antibodies. Sections were incubated
with secondary biotinylated antibodies, and then with Vec-
tastain avidin–biotin complex conjugated with horseradish
peroxidase (Vector Laboratories) and visualized using 3,3-
diaminobenzidine. Sections were viewed and photographed on
an Axioskop microscope and Carl Zeiss digital camera using
Axiovision software.
Immunofluorescence. Colocalization between cell-
specific antigens was investigated using 2-, 3-, and 4-color
immunofluorescence labeling. Cells were grown in 8-well
chamber slides, fixed with ice-cold methanol for 2 minutes,
blocked with normal serum, and incubated with primary
antibodies for 1 hour at room temperature. Primary anti-
bodies were raised in different species in each experiment, and
appropriate secondary antibodies conjugated to Alexa Fluor
fluorophores (Life Technologies) were used. Vectashield
mounting medium containing DAPI (Vector Laboratories)
was used to mount the slides. Cells were viewed and photo-
graphed on an Axioskop Z fluorescence microscope with an
Axiocam digital camera in combination with Axiovision soft-
ware (Carl Zeiss).
Deconvolution of Z-stacks was used to assess nuclear/
cytoplasmic immunostaining. Analysis of staining of the nuclei
was carried out using ImageJ software. Four separate fields
of view were imaged in triplicate. The total number of nuclei
stained with DAPI was calculated using the software and
verified by eye. The total number of fluorescent cells or nuclei
was then determined using the software, with verification by
eye. The mean  SEM values for nuclear/cytoplasmic staining
were calculated, and Student’s t-test was applied for compari-
sons of the data between groups.
Migration assays. Dermal fibroblasts were either left
untreated, treated with scrambled control siRNA, or treated
with specific siRNA for JunB, prior to migration experiments.
Migration into a scratch wound was performed using a 96-well
floating-pin transfer device with a pin diameter of 1.58 mm.
The pin array was placed in the top corner of a well, pushed
down into the 96-well plate to engage all pins, and then pulled
toward the user. Plates were returned to the tissue-culture
incubator for 48 hours, and migration was assessed in the
presence of mitomycin C (5 g/ml; Sigma). Images of the
Figure 1. Structure and function of the far-upstream enhancer (FUE)
of human COL1A2. A, Schematic representation of the FUE genomic
location shows 3 open chromatin areas (footprint 1 [F1]–F3) along
with known DNase hypersensitive sites (arrowheads), the critical
activator protein 1 (AP-1) site in F2, and the position of the proximal
promoter (PP). B and C, LacZ reporter gene constructs driven by the
thymidine kinase (TK) promoter alone or fused to the COL1A2-FUE
(21.1/18.8pLAC-TK) (B) or LacZ reporter gene constructs driven by
the COL1A2 proximal promoter (C) were transfected into dermal
fibroblasts from normal healthy controls or patients with systemic
sclerosis (SSc) (n  3 per group), and response to treatment with
transforming growth factor  (TGF; 4 ng/ml) (black bars) or without
TGF (gray-shaded bars) was measured. In B, cotransfection of a
Smad7 expression vector was also included. In C, a mutated COL1A2-
FUE (21.1/18.8pLAC-AP-1-20.03) with the AP-1 site abolished
(red “x”) was also included. Bars show the mean  SEM of quadru-
plicate experiments. Statistical significance was assessed using Stu-
dent’s t-test. D, Intracellular type I procollagen expression was as-
sessed by immunohistochemical staining of skin sections from healthy
control subjects or patients with active diffuse SSc. Insets show IgG
controls.
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wounds were obtained at 24 hours of culture, and the extent of
wound closure was assessed (using the Wimasis Image Analysis
platform, available at http://www.wimasis.com), with results
expressed as the percentage of wounded area covered.
Inhibition of mTOR, Akt, and GSK-3 signaling. Nor-
mal and SSc dermal fibroblasts were serum-starved overnight
and treated with an inhibitor of mTOR (20 nM rapamycin;
Sigma), phospho-Akt (50 nM GSK690693; Seleckchem), GSK-3
(inhibitor VII, 500 nM AR-A014418; Merck-Calbiochem), and
proteasome (500 nM MG-132; Merck-Calbiochem).
Statistical analysis. Results are expressed as the
mean  SEM. Student’s unpaired t-tests were used for com-
parison between 2 groups. P values less than 0.05 were con-
sidered statistically significant.
RESULTS
Type I collagen expression in SSc skin. We have
previously shown that overexpression of type I collagen
in the skin tissue of adult patients is regulated at the
transcriptional level by the COL1A2-FUE, which drives
expression in a spatial and temporal manner (5). More
recently, we demonstrated that this complex regulatory
region contains an AP-1–dependent TRE (6).
The TRE sequence of the human COL1A2-
FUE (shown in the schematic representation in Figure
1A) is located between 19.2 kb and 20.0 kb upstream of
the transcriptional origin in a previously identified re-
gion of open chromatin, footprint 2 (F2) (2). Fine-
mapping of the region identified a putative AP-1 site
that was shown to mediate the TGF response (6).
Reporter gene constructs containing the wild-
type human COL1A2 enhancer region and the heterol-
ogous thymidine kinase (TK) promoter, lacking a Smad-
dependent TRE (21.1/18.8pLAC-TK), were used to
assess the TRE in the FUE region. These constructs
were cotransfected with Smad7 expression vectors into
normal or SSc dermal fibroblasts, and the response to
TGF treatment was assessed (Figure 1B). The results
indicated that the COL1A2-FUE was activated by TGF
in both normal and scleroderma fibroblasts. The addi-
Figure 2. Binding of JunB and c-Jun to the AP-1 site of the COL1A2 enhancer. A, Electrophoretic mobility shift assays (EMSAs) were carried out
using a probe for the COL1A2-FUE AP-1 site. Nuclear extracts from dermal fibroblasts of normal healthy controls and patients with SSc (n  3
per group) treated with or without TGF (2 ng/ml) were incubated with 32P-labeled probe and analyzed by EMSA. Control experiments using
unlabeled (cold) oligonucleotide (oligo) probe as a competitor or a 32P-labeled probe containing a mutated AP-1 site were included. B, Supershift
EMSA was performed to confirm the identity of the transcription factors binding the AP-1 probe. Nuclear extracts (n  3 per group) were
preincubated with non-neutralizing antibodies against c-Jun, JunB, or JunD prior to adding the labeled probe. C, Chromatin immunoprecipitation
assays were carried out with specific antibodies (IgG) against RNA polymerase II (Pol II), c-Jun, or JunB, using DNA from normal and SSc dermal
fibroblasts (n  3 per group) treated with or without TGF (2 ng/ml), with expression assessed in the F2 and proximal promoter sites. Nonspecific
antibody (IgG Con) and nonimmunoprecipitated DNA (input) were included as controls. D, Schematic representations show a putative mechanism
for enhanced COL1A2 expression in response to TGF in SSc fibroblasts, mediated by c-Jun and JunB and involving the FUE AP-1 site, compared
to basal COL1A2 expression in normal fibroblasts. See Figure 1 for other definitions.
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tion of Smad7 had no effect, thus indicating that the
activation of the upstream TRE is independent of
Smad. Moreover, TGF treatment was not required for
induction of COL1A2-FUE activity in SSc fibroblasts,
suggesting that the factors induced by TGF were
constitutively present.
To examine the role of the AP-1 site, we used
reporter gene constructs containing the wild-type human
COL1A2 enhancer region fused to the natural COL1A2
proximal promoter (21.1/18.8pLAC) or a mutant con-
struct in which the TRE/AP-1 site was deleted (21.1/
18.8pLAC-AP-1-20.03). In both normal and SSc fibro-
blasts, COL1A2-FUE activity was abolished in the pres-
ence of the AP-1 mutation, resulting in attenuated
reporter gene activity upon the addition of TGF. Im-
portantly, the higher basal reporter gene activity in SSc
cells was also effectively abolished in the presence of the
mutant construct (Figure 1C).
Consistent with these results, immunohistochem-
ical staining of skin sections for intracellular procollagen
revealed an overexpression of intracellular type I pro-
collagen in the SSc dermis compared to the normal
dermis (Figure 1D). The differences were particularly
pronounced in fibroblasts located in the suprabasal layer
(Figure 1D).
Role of type I collagen enhancer TRE in sclero-
derma dermal fibroblasts. We carried out EMSAs of
nuclear extracts from normal and SSc dermal fibroblasts
using 32P-labeled oligonucleotide probes of the COL1A2
wild-type sequence containing the putative AP-1 TRE
(Figure 1A) after the cells had been cultured in the
presence or absence of TGF (2 ng/ml). The EMSA
profile differed between normal and SSc nuclear extracts
(Figure 2A). The SSc gel-shift pattern resembled that of
nuclear extracts from TGF-treated normal fibroblasts
(Figure 2A). A single-shifted band of diminished inten-
sity was observed in untreated normal nuclear extracts,
compared to 4 shifted bands in SSc nuclear extracts and
TGF-treated normal nuclear extracts. The band spec-
ificity was tested with the addition of unlabeled oligo-
nucleotide (cold competitor), which competes with the
32P-labeled probe. When an AP-1 mutant probe was
used, no shifted bands were apparent in either normal or
SSc nuclear extracts.
Supershift assays using specific antibodies (Fig-
ure 2B) revealed that normal nuclear extracts bound
c-Jun and, to a lesser extent, JunD. In SSc, c-Jun binding
was greatly reduced, and JunB, which was previously
absent in normal nuclear extracts, accounted for 2 of the
shifted bands. JunD binding was more pronounced in
SSc extracts (Figure 2B). These gel-shift findings suggest
that in SSc dermal fibroblasts or in normal nuclear
extracts treated with TGF, JunB binding replaces c-Jun
binding on the AP-1 site in the COL1A2 upstream
enhancer.
These results were confirmed using ChIP assays,
which demonstrated the association of the F2 region in
the FUE with the proximal promoter and the transcrip-
tional machinery. ChIP was conducted on explanted
Figure 3. Protein expression levels of AP-1 family members in dermal
fibroblasts from healthy controls and patients with diffuse SSc. A, Expres-
sion of c-Jun, JunB, JunD, c-Fos, Fra-1, and Fra-2 in normal and SSc
fibroblasts (n  10 per group) was assessed by Western blotting. Five
representative samples are shown, with GAPDH used as the loading
control. B,Western blotting was used to assess a normal fibroblast line for
protein expression at various times over a 24-hour period after serum
starvation and addition of TGF (2 ng/ml). C and D, Top, Three-color
immunofluorescence staining was used to assess the cellular location of
c-Jun (C) or JunB (D) in normal and SSc dermal fibroblasts (n  3 per
group; representative results shown). DAPI was used to stain nuclei, and
phalloidin (Phal) was used to stain actin filaments. Bottom, The number
of cells showing nuclear or cytoplasmic staining was assessed and ex-
pressed as a percentage of the total number of cells. Bars show the
mean  SEM aggregate results from 2 independent experiments. Statis-
tical significance was assessed using Student’s t-test. See Figure 1 for other
definitions.
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normal or SSc fibroblasts that were left untreated or
treated with TGF and then incubated with specific
antibodies against RNA polymerase II, c-Jun, and JunB.
As expected, RNA polymerase II coprecipitated with the
proximal promoter in both normal and SSc cells with or
without TGF treatment (Figure 2C). RNA polymerase
II also coprecipitated with the F2 enhancer sequence,
despite not being able to bind the enhancer directly,
thereby demonstrating the interaction between the tran-
scriptional machinery in the promoter with the factors
bound to the F2 region. Thus, the data confirm the
coalescence of the enhancer/promoter.
In normal fibroblasts, in the absence of TGF,
c-Jun appeared to be mediating this interaction, whereas
there was no JunB binding on the F2 enhancer sequence
(Figure 2C). TGF treatment resulted in a decrease in
c-Jun binding and an increase in JunB binding (Figure
2C). In SSc fibroblasts, c-Jun binding was greatly dimin-
ished on both the enhancer and the proximal promoter
(Figure 2C). In contrast, JunB appeared to bind the F2
region in the absence of TGF treatment and was fur-
ther increased upon the addition of TGF (Figure 2C).
Based on these findings, a simplified model of
c-Jun/JunB regulation can be put forward (Figure 2D),
in which basal expression of COL1A2 occurs in normal
fibroblasts as a result of c-Jun being bound to the AP-1
site (20.0 kb) in the F2 region. However, in SSc dermal
fibroblasts or in TGF-treated normal fibroblasts, the
AP-1 site is occupied by JunB, resulting in a stronger
interaction of factors bound to the FUE with the tran-
scriptional machinery in the proximal promoter, and
ultimately leading to higher expression of COL1A2.
Expression levels of AP-1 family members in
scleroderma. We tested the expression levels of AP-1
family members in dermal fibroblasts explanted from
biopsy specimens that were obtained from a cohort of
patients with active diffuse cutaneous SSc. Western blot
analysis revealed that protein levels of c-Jun, JunD,
cFos, Fra-1, and Fra-2 were the same in both the control
and SSc cohorts, and only the level of JunB differed.
JunB was absent in the control cohort (Figure 3A). The
time course of TGF treatment of normal fibroblasts
showed that JunB was the only AP-1 family member that
was induced by TGF treatment over 24 hours (Figure
3B).
We examined the intracellular distribution of
c-Jun and JunB in normal and SSc dermal fibroblasts
(Figures 3C and D). In normal fibroblasts, c-Jun expres-
sion was mainly nuclear, and JunB expression was low.
In SSc fibroblasts, cytoplasmic c-Jun expression was
observed in 90% of cells (Figure 3C), and concomi-
tantly, 90% of the SSc cells showed nuclear expression
of JunB (Figure 3D).
We determined the expression and distribution of
JunB, c-Jun, and JunD in sections of dermal biopsy
specimens obtained from healthy controls and patients
with diffuse cutaneous SSc. The expression of c-Jun was
observed in the dermis of both normal control subjects
and patients with diffuse cutaneous SSc (Figure 4B).
Similarly, nuclear expression of JunD was observed in
Figure 4. Protein expression of activator protein 1 family members in skin biopsy specimens from healthy controls and patients with diffuse systemic
sclerosis (SSc). Expression of JunB (A), c-Jun (B), and JunD (C) was determined by immunohistochemistry in skin biopsy specimens (n  5 per
group) using specific antibodies, visualized using 3,3-diaminobenzidine (brown staining) and counterstained with hematoxylin. Images are shown
at low (top panels) and high (bottom panels) magnification. Representative images from 1 patient are shown. Insets, Isotype control antibodies used
at the same concentration as the primary antibodies. Arrows indicate positive expression. Bars  100 M.
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dermal fibroblasts and around vessels in the dermis of
both normal subjects and patients with diffuse cutaneous
SSc (Figure 4C). However, JunB expression was absent
from the dermis of normal subjects, whereas in SSc
patients, JunB was highly expressed in dermal fibroblasts
and around blood vessels (Figure 4A).
Inhibition of JunB in SSc. Having established the
differential expression of JunB, we tested the functional
role of JunB in normal and scleroderma dermal fibro-
blasts. We used siRNA to target JunB in dermal fibro-
blasts from healthy controls and patients with diffuse
cutaneous SSc (Figure 5A). Normal fibroblasts ex-
pressed only low levels of JunB, except when treated
with TGF. After treatment with TGF, normal fibro-
blasts that were either left untreated or transfected with
scrambled control siRNA expressed JunB and type I
collagen. However, when JunB was inhibited by specific
siRNA for JunB in normal fibroblasts, there was a
dose-dependent decrease in the expression of type I
collagen and connective tissue growth factor (CTGF;
CCN2) (Figure 5A).
When fibroblasts from patients with diffuse cuta-
neous SSc were transfected with scrambled control
siRNA, expression of JunB and type I collagen was
observed. SSc fibroblasts also expressed JunB regardless
of whether TGF was added. Inhibition of JunB using
specific siRNA for JunB resulted in a dose-dependent
decrease in type I collagen and CTGF expression.
Expression of c-Jun and JunD was unaffected in
both normal and scleroderma fibroblasts in which JunB
had been inhibited. This suggests that JunB is involved
in the activation of fibroblasts and in the establishment
of the fibrotic phenotype.
We also assessed the effect of JunB inhibition on
fibroblast migration in a scratch wound assay (Figure
5B). Scratch wounds were generated on a fibroblast
monolayer using a scratch tool that creates equal wound
areas allowing for cell migration. Normal fibroblasts that
were activated with TGF and then transfected with
scrambled control siRNA (25 nM) covered a mean 
SEM 92.2  1.98% of the scratch area after 48 hours.
Inhibition of JunB with siRNA for JunB (25 nM) in
normal fibroblasts resulted in only 26.6 4.5% coverage
after 48 hours. Scleroderma fibroblasts that were not
treated with TGF but were transfected with scrambled
control siRNA covered 91.25  3.35% of the scratch
wound area, whereas when the cells were transfected
with siRNA for JunB, only 20.75  1.34% of the scratch
area was covered after 48 hours. Similar results were
obtained with SSc fibroblasts that were treated with
TGF and then transfected with scrambled control
siRNA (96.75  2.1% area coverage) or with siRNA for
JunB (19.25  1.72% area coverage). Interestingly,
untreated normal fibroblasts, when transfected with
scrambled control siRNA, covered 70.6  4.1% of the
scratch area after 48 hours, whereas those transfected
with siRNA for JunB covered 47.8 3.3% of the scratch
area. Since the expression of JunB in normal fibroblasts
grown in confluent monolayers was low, one can specu-
late that this discrepancy could be attributed to a
Figure 5. Effect of JunB down-regulation by small interfering RNA
(siRNA) on the expression of fibrotic markers and cell migration. A,
JunB siRNA (siJunB) was used at concentrations of 10 nM and 25 nM,
and scrambled control siRNA (siControl) was used at 25 nM. The
levels of JunB, c-Jun, and JunD, as well as the fibrotic markers type I
collagen (Col1) and connective tissue growth factor (CCN2), in cells
from normal healthy controls and patients with SSc (n  3 per group)
with or without treatment with TGF were assessed by Western
blotting. Six different cell lines were used; representative images are
shown. B, Migration of normal and SSc fibroblasts was assessed by in
vitro scratch wound assay. Top, Fibroblasts from normal healthy
controls and patients with SSc (n  3 per group) were either left
untreated or treated with TGF and transfected with siJunB (20 nM)
or siControl (20 nM). Six different cell lines were used; representative
images are shown. Each assay was carried out in triplicate. Bottom,
The percentage of the scratch area covered by migrating fibroblasts
was measured after 24 hours. Bars show the mean  SEM. Statistical
significance was assessed using Student’s t-test. See Figure 1 for other
definitions.
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localized increase in JunB expression within cells adja-
cent to the scratch wound, where contact inhibition is
abolished and the migration process is initiated.
Mechanism of JunB overexpression in SSc. Al-
though JunB protein was overexpressed, JunB messen-
ger RNA levels were not significantly different between
normal and SSc fibroblasts (Figure 6A). We hypothe-
sized that JunB may be regulated by a posttranslational
mechanism. Previous studies in patients with cancer
have shown that JunB is regulated by GSK-3 phosphor-
ylation, leading to JunB degradation via the proteasome
(22,23). Inhibiting GSK-3 phosphorylation using the
specific inhibitor AR-A14418 increased the level of
JunB protein in normal fibroblasts, making it roughly
equal to the level observed in SSc fibroblasts (Figure
6B). Treatment with the proteasome inhibitor MG-132
for 3 hours produced similar results. Interestingly, nei-
ther inhibitor appeared to influence the levels of c-Jun
(Figure 6B) or JunD (results not shown).
Phospho-Akt, which is known to phosphorylate
and inactivate GSK-3, was up-regulated in SSc fibro-
blasts. We found that the levels of both phospho-Akt
and phospho–GSK-3 were higher in SSc fibroblasts
compared to normal fibroblasts (Figure 6C).
To test the involvement of Akt phosphorylation,
we stimulated SSc fibroblasts with TGF in the presence
or absence of 50 nM GSK690693 (Akt inhibitor). After
treatment of SSc fibroblasts with GSK690693, we ob-
served reduced phosphorylation of both Akt and
GSK-3 and lower expression of JunB (Figure 6C).
Since Akt and GSK-3 are both downstream of
the mTOR pathway, we also utilized rapamycin to
investigate the role of mTOR in the accumulation of
JunB in SSc fibroblasts. Treatment of SSc fibroblasts
with rapamycin resulted in decreased levels of JunB and
type I collagen protein expression, in a dose-dependent
manner. Rapamycin treatment had no effect on the
levels of c-Jun and JunD (Figure 6C).
Figure 6. Pathways that lead to JunB overexpression in patients with SSc. A, JunB mRNA levels were assessed in untreated fibroblasts from normal
healthy controls and patients with diffuse SSc. Bars show the mean  SEM (n  6 per group). B, Fibroblasts from normal healthy controls and
patients with diffuse SSc (n  3 per group) were serum-starved and then left untreated or treated for 3 hours with the specific glycogen synthase
kinase 3 (GSK-3) inhibitor AR-A14418 (AR-A) or with the proteasome inhibitor MG-132. Expression of JunB and c-Jun was assessed by Western
blotting. C, The role of mammalian target of rapamycin (mTOR)/Akt signaling in JunB expression was assessed by Western blotting. Left, Western
blot showing the difference in Akt and GSK-3 phosphorylation between serum-starved SSc and normal fibroblasts. Middle, Western blot of
serum-starved SSc fibroblasts left untreated (Unt) or treated with TGF (2 ng/l) for 16 hours, prior to removal of TGF and treatment with the
specific Akt inhibitor GSK690693 (50 M) for 3 hours. Right, Western blot of serum-starved normal or SSc fibroblasts left untreated or treated with
2 different concentrations of rapamycin (Rap) for 6 hours, prior to harvesting each protein. All Western blots are representative of at least 3
independent experiments. D, Schematic diagrams show the regulation of JunB levels by TGF, mTOR, Akt, and GSK-3 in normal and SSc
fibroblasts. PI3K  phosphatidylinositol 3-kinase; AUG  adenosine, uridine, and guanosine; P  phosphorylated; UBT  ubiquitinated (see
Figure 1 for other definitions).
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We also investigated the effect of rapamycin on
the cellular localization of JunB, c-Jun, and JunD in
normal and SSc fibroblasts (see Supplementary Figure 1,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38897/
abstract). In normal fibroblasts, in which there was no
JunB expression and c-Jun was mainly located in the
nucleus, rapamycin treatment had no effect on the
phenotype of the cells (low levels of type I procollagen
and -smooth muscle actin [-SMA]). However, in SSc
fibroblasts, in which the cells displayed a fibrotic pheno-
type (high levels of type I procollagen and -SMA) and
there was high nuclear expression of JunB and cyto-
plasmic expression of c-Jun, rapamycin treatment re-
sulted in a normalizing effect, whereby the nuclear levels
of c-Jun increased, the nuclear levels of JunB decreased,
and both type I collagen and -SMA were down-
regulated. Taken together, these data show that in SSc
dermal fibroblasts, activated mTOR induces the accu-
mulation of JunB by inducing the phosphorylation of
Akt, which in turn phosphorylates and deactivates GSK-
3, thereby preventing the degradation of JunB by the
proteasome. In contrast, in normal fibroblasts, GSK-3
is active and targets JunB for proteasomal degradation
(Figure 6D).
DISCUSSION
The excessive deposition of type I collagen is a
common pathologic feature of all fibrotic diseases. In
SSc, collagen deposition in the dermis and the resultant
fibrosis is an important contributor to the chronic dis-
ease process, leading to manifestations such as ulcers,
reduced hand function, and a significant decrease in
quality of life.
In this study, we show that the expression and
deposition of type I collagen is potently regulated by
the COL1A2-FUE, which interacts with the proximal
promoter of the gene to initiate transcription. We pre-
viously showed that this regulatory element is required
in order to reactivate COL1A2 expression in adult
dermal tissue during processes of wound healing, repair,
or pathologic development (5). We have now deter-
mined that within this enhancer lies a small regulatory
sequence containing an AP-1 consensus site, which is
essential for enhancer function and controls the over-
expression of COL1A2 by scleroderma fibroblasts. Pre-
viously, we described a mechanism in which TGF
increases COL1A2 expression by activating JunB ex-
pression, which leads to exchange of c-Jun for JunB,
thus stabilizing and enhancing promoter/enhancer co-
alescence (6). The significance of these study findings is
that it uncovers the unifying mechanism underlying
the function of AP-1 family members in the control of
collagen expression.
Although both JunB and c-Jun can bind the
AP-1–FUE site and direct collagen expression, JunB
mediates enhanced expression, whereas c-Jun is respon-
sible for basal expression levels. In SSc dermal fibro-
blasts, constitutive JunB expression is responsible for
enhanced collagen expression. Other investigators have
reported that AP-1 members such as JunD, c-Jun, and
Fra-2 are important in scleroderma dermal fibrosis
(17–20,24). These studies are consistent with our find-
ings. Collagen gene regulation is complex and involves
several pathways, some of which are AP-1 dependent,
that are likely to have an impact on each other. Indeed,
although COL1A1 and COL1A2 are on separate chro-
mosomes, they are coordinately expressed via mecha-
nisms not fully understood. Herein we have focused on
the COL1A2 enhancer/proximal promoter interface,
finding that although c-Jun occupied the COL1A2 en-
hancer TRE under normal conditions, it was JunB that
was critical in activating and enhancing type I collagen
expression in SSc dermal fibroblasts.
We also found that specific inhibition of JunB by
siRNA resulted in decreased type I collagen expression
and a decreased ability of SSc dermal fibroblasts to
migrate into a scratch wound, thus demonstrating the
importance of JunB for many normal dermal fibroblast
functions. We therefore suggest that JunB orchestrates
the activation of the COL1A2 enhancer. Consistent with
previous reports, it is likely that other AP-1 family
members are also necessary for FUE activity and form
part of the regulatory complex that assembles in the
enhancer, but their action is conditional, requiring the
presence of JunB, which is the critical regulatory com-
ponent.
JunB was originally discovered for its role in
cancer as an early growth-response gene that inhibited
cell proliferation and transformation and antagonized
c-Jun activity. However, the findings from recent reports
suggest that JunB has oncogenic activities, such as pro-
moting proliferation in cutaneous lymphomas (25), and
it can cooperate with c-Jun in the development of
fibrosarcoma (26).
In this study, we identified aberrant proteasomal
targeting, rather than direct transcriptional activation, as
the reason behind the constitutive JunB expression in
scleroderma skin. Indeed, there are several examples of
JunB regulation by the ubiquitin–proteasome pathway
in the literature (22,27,28). GSK-3 phosphorylation of
ROLE OF JunB IN SSc 251
JunB is therefore likely to be one of the critical events
determining the difference in collagen deposition be-
tween normal and SSc fibroblasts. Our results show that
Akt activity plays an important role by inactivating
GSK-3 through phosphorylation.
Consistent with previous reports highlighting the
role of the mTOR pathway in type I collagen regulation
(29) and in animal models of scleroderma (30), we found
that rapamycin was effective at reducing JunB expres-
sion and collagen production in SSc fibroblasts. The
therapeutic potential of rapamycin was recently con-
firmed in human patients. A small, randomized, single-
blind pilot study of rapamycin in patients with early
diffuse SSc demonstrated that rapamycin significantly
improved both the modified Rodnan skin thickness
score and the patient’s global assessment of health (31).
In conclusion, the results of this study demon-
strate that type I collagen overexpression in scleroderma
skin is regulated, in part, by the persistent expression of
JunB, which occupies the TRE in the COL1A2 en-
hancer. The constitutive up-regulation of JunB expres-
sion in SSc fibroblasts appears to be attributable to
aberrant signaling of GSK-3 through the mTOR/Akt
pathway, leading to failure of the mechanism that nor-
mally targets JunB for proteasomal degradation. Inhibi-
tion of Akt or mTOR results in decreased levels of JunB
and type I collagen and a normalization of the fibrotic
phenotype of scleroderma fibroblasts in vitro, whereas
inhibition of GSK-3 results in constitutive expression of
JunB in normal fibroblasts. In summary, these findings
add yet another layer of complexity in the regulation of
type I collagen by AP-1 transcription factors and fibrosis
(18–20,24), reinforcing the view that these pathways
have translational utility for the treatment of SSc.
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